We’re watching positive data for Ozempic, a Lilly factory expansion

It’s an honor to fill in for Ed Silverman this morning. There is just one Pharmalot, however when he’s out, his fellow STAT espresso and tea drinkers step in to verify your morning cup of pharma information is uninterrupted. It’s Friday, the final workday earlier than the lengthy Memorial Day weekend right here within the U.S. (and so we’ll subsequent land in your inbox Tuesday). If you happen to haven’t converted to iced espresso but, please accomplish that. In fact, in Boston, we imbibe our caffeine frosty all yr spherical. Let’s go!

Novo Nordisk’s Ozempic reduce the danger of cardiovascular-related deaths by 29% and all-cause deaths by 20% in a trial of sufferers with kind 2 diabetes and continual kidney illness, suggesting it could supply some added advantages over different lessons of medication authorized to deal with this inhabitants, STAT studies. Given the examine parameters, this suggests that over three years, 39 folks would should be handled to stop one demise from any trigger, in keeping with new outcomes introduced Friday at a gathering of the European Renal Affiliation and printed within the New England Journal of Medication.

Eli Lilly mentioned Friday that it’s investing an extra $5 billion to develop an Indiana manufacturing facility to spice up manufacturing of its blockbuster weight problems and diabetes medicines Zepbound and Mounjaro, the corporate studies. Excessive demand for the medicine has created provide shortages nationwide. Lilly mentioned the brand new capital spending will increase the whole funding within the manufacturing facility to $9 billion, and is the one largest funding in drug manufacturing in U.S. historical past.